Verve Therapeutics
About Us
Why Heart Disease
Approach
Pipeline
Culture & Careers
News
In vivo CRISPR editing with no detectable genome-wide off-target mutations
Post navigation
Previous Post
Previous
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Next Post
Next
Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
Home
About Us
Why Heart Disease
Approach
Pipeline
Culture & Careers
News
Contact Us